, Espérance de vie -Mortalité ? Tableaux de l'économie française | Insee, 2018.

A. Charlemagne, J. Blacher, A. Cohen, J. Collet, F. Diévart et al., Epidemiology of atrial fibrillation in France: Extrapolation of international epidemiological data to France and analysis of French hospitalization data, Arch Cardiovasc Dis, vol.104, issue.2, pp.115-139, 2011.

S. Bun, D. G. Latcu, F. Marchlinski, and N. Saoudi, Atrial flutter: more than just one of a kind, Eur Heart J, vol.36, issue.35, pp.2356-63, 2015.

, Les 10 principales causes de mortalité, 2018.

, Accident vasculaire cérébral (AVC) [Internet]. Inserm -La science pour la santé, 2018.

G. De-pouvourville, Coût de la prise en charge des accidents vasculaires cérébraux en France. Arch Cardiovasc Dis Suppl, vol.8, pp.161-169, 2016.

A. Rubboli, M. Colletta, J. Herzfeld, P. Sangiorgio, D. Pasquale et al., Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis, Centre d'épidémiologie sur les causes médicales de décès. Résultats de la requête : Effectifs de décès, vol.18, pp.193-202, 2007.

T. Y. Wang, L. A. Robinson, F. Ou, M. T. Roe, E. M. Ohman et al., Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry, Am Heart J, vol.155, issue.2, pp.361-369, 2008.

F. Pérez-gómez, A. E. Berjón, J. Iriarte, J. A. Zumalde, J. Salvador et al., Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study, J Am Coll Cardiol, vol.44, issue.8, pp.1557-66, 2004.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, vol.18, pp.1609-78, 2016.

, Ministère de la santé et des sports. La prévention et la prise en charge des accidents vasculaires cérébraux en France, 2018.

P. A. Wolf, R. D. Abbott, and W. B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991.

P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm et al., Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, vol.9, pp.1006-1029, 2007.

S. Knecht, C. Oelschläger, T. Duning, H. Lohmann, J. Albers et al., Atrial fibrillation in strokefree patients is associated with memory impairment and hippocampal atrophy, Eur Heart J, vol.29, issue.17, pp.2125-2157, 2008.

P. Appelros, I. Nydevik, and M. Viitanen, Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year, Stroke, vol.34, issue.1, pp.122-128, 2003.

H. Vadmann, P. B. Nielsen, S. P. Hjortshøj, S. Riahi, L. H. Rasmussen et al., Atrial flutter and thromboembolic risk: a systematic review, Heart, vol.101, issue.18, pp.1446-55, 2015.

G. Lip, L. Frison, J. L. Halperin, and D. A. Lane, Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort, Stroke, vol.41, issue.12, pp.2731-2739, 2010.

B. F. Gage, Y. Yan, P. E. Milligan, A. D. Waterman, R. Culverhouse et al., Clinical classification schemes for predicting hemorrhage, Am Heart J, vol.151, issue.3, pp.713-722, 2006.

R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De-vos, H. Crijns et al., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, issue.5, pp.1093-100, 2010.

M. C. Fang, A. S. Go, Y. Chang, L. H. Borowsky, N. K. Pomernacki et al., A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study, J Am Coll Cardiol, vol.58, issue.4, pp.395-401, 2011.

Z. Hijazi, J. Lindbäck, J. H. Alexander, M. Hanna, C. Held et al., The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation, Eur Heart J, vol.37, issue.20, pp.1582-90, 2016.

A. J. Camm, G. Lip, D. Caterina, R. Savelieva, I. Atar et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, vol.33, issue.21, pp.2719-2766, 2012.

J. A. Cairns, S. Connolly, S. Mcmurtry, M. Stephenson, and M. Talajic, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter, Can J Cardiol, vol.27, issue.1, pp.74-90, 2011.

G. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek et al., Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis, Thromb Haemost, vol.106, issue.6, pp.997-1011, 2011.

A. J. Camm, P. Kirchhof, and G. Lip, Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Developed with the special contribution of the European Heart Rhythm Association (EHRA), vol.31, pp.2369-429, 2010.

G. Lip, J. L. Halperin, H. Tse, and . The, European Society of Cardiology Guidelines on the Management of Atrial Fibrillation: An Evolution or Revolution? CHEST, vol.139, pp.738-779, 2010.

, HAS. Fibrillation auriculaire non valvulaire-Quelle place pour les anticoagulants oraux non antivitamine K : apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®), 2013.

. Agence-nationale-de-sécurité-du and . Médicament, Les anticoagulants en France en 2014: état des lieux, synthèse et surveillance, p.78, 2014.

. Préviscan, (fluindione) et risque immuno-allergique -Point d'Information -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2018.

H. Baumgartner, P. J. Holm, B. Iung, P. Lancellotti, E. Lansac et al., ESC/EACTS Guidelines for the management of valvular heart disease, Eur Heart J, vol.38, issue.36, p.53, 2017.

H. Autorité-de-santé, Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier, 2008.

S. J. Connolly, J. Pogue, J. Eikelboom, G. Flaker, P. Commerford et al., Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation, vol.118, issue.20, pp.2029-2066, 2008.

C. Van-walraven, J. A. Oake, N. Fergusson, D. Forster, and A. J. , Effect of study setting on anticoagulation control: a systematic review and metaregression, Chest, vol.129, issue.5, pp.1155-66, 2006.

, Prise en charge des surdosages, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier, HAS, 2008.

S. Connolly, J. Pogue, R. Hart, M. Pfeffer, and S. Hohnloser, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet Lond Engl, vol.367, issue.9526, pp.1903-1915, 2006.

R. G. Hart, L. A. Pearce, and M. I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, vol.146, issue.12, pp.857-67, 2007.

J. Mant, F. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet Lond Engl, 2007.

, Aug, vol.11, issue.9586, pp.493-503

, The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

H. Autorité-de-santé, Fibrillation auriculaire non valvulaire Quelle place pour les anticoagulants oraux ?, 2016.

S. Roullet, Rev Prescrire. Idarucizumab (Praxbind°). Ne pas trop compter dessus comme antidote du dabigatran, vol.36, pp.494-503, 2015.

H. Autorité-de-santé, Direction de l'Evaluation Médicale, Economique et de Santé Publique, p.25, 2016.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, N Engl J Med, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, J. H. Alexander, J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, vol.365, issue.11, pp.981-92, 2011.

R. P. Giugliano, C. T. Ruff, E. Braunwald, S. A. Murphy, S. D. Wiviott et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, vol.369, issue.22, pp.2093-104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, vol.361, issue.12, pp.1139-51, 2009.

, Commission de la transparence, pp.1-22, 2012.

, Commission de la transparence, pp.1-25, 2014.

. Haute-autorité-de-santé and . Xarelto, Commission de la transparence, pp.1-24, 2012.

H. Autorité-de-santé, Commission de la transparence, pp.1-31, 2016.

, Commission de la transparence, p.43, 2014.

C. T. Ruff, R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. The Lancet, vol.383, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

C. Nationale-d'assurance-maladie, Etude de l'Assurance Maladie sur l'utilisation des nouveaux anticoagulants oraux, 2013.

H. Autorité-de-santé, Les anticoagulants oraux antivitamine K restent la référence dans la fibrillation auriculaire non valvulaire, p.3013, 2018.

K. Thygesen, J. S. Alpert, A. S. Jaffe, B. R. Chaitman, J. J. Bax et al., Fourth universal definition of myocardial infarction, Eur Heart J, vol.40, issue.3, pp.237-69, 2018.

B. Ibanez, S. James, S. Agewall, M. J. Antunes, C. Bucciarelli-ducci et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC), Eur Heart J, vol.39, issue.2, pp.119-77, 2017.

F. Neumann, M. Sousa-uva, A. Ahlsson, F. Alfonso, A. P. Banning et al., ESC/EACTS Guidelines on myocardial revascularization, Eur Heart J, vol.40, issue.2, pp.87-165, 2018.

F. W. Mohr, M. Morice, A. P. Kappetein, T. E. Feldman, E. Ståhle et al., Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial, Lancet Lond Engl, vol.381, issue.9867, pp.629-667, 2013.

D. J. Angiolillo, A. Fernandez-ortiz, E. Bernardo, C. Ramírez, M. Sabaté et al., Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment, Diabetes, vol.54, issue.8, pp.2430-2435, 2005.

R. The and . Group, Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease, Lancet Lond Engl, vol.336, issue.8719, pp.827-857, 1990.

S. Juul-möller, N. Edvardsson, B. Jahnmatz, A. Rosén, S. Sørensen et al., Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group, Lancet Lond Engl, vol.340, issue.8833, pp.1421-1426, 1992.

J. A. Cairns, M. Gent, J. Singer, K. J. Finnie, G. M. Froggatt et al., Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial, N Engl J Med, vol.313, issue.22, pp.1369-75, 1985.

H. D. Lewis, J. W. Davis, D. G. Archibald, W. E. Steinke, T. C. Smitherman et al., Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study, N Engl J Med, vol.309, issue.7, pp.396-403, 1983.

M. S. Sabatine, C. H. Mccabe, C. M. Gibson, and C. P. Cannon, Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial, Am Heart J, vol.149, issue.2, pp.227-260, 2005.

Z. M. Chen, L. X. Jiang, Y. P. Chen, J. X. Xie, H. C. Pan et al., Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet Lond Engl, vol.366, issue.9497, pp.1607-1628, 2005.

S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni et al., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 2001.

, Aug, vol.16, issue.7, pp.494-502

S. R. Steinhubl, P. B. Berger, J. T. Mann, E. Fry, A. Delago et al., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial, JAMA, vol.288, pp.2411-2431, 2002.

. European, Guidelines on myocardial revascularization -Supplementary Data, European Heart Journal, 2018.

J. Collet, T. Cuisset, G. Rangé, C. G. Elhadad, S. Pouillot et al., Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting, N Engl J Med, vol.367, issue.22, pp.2100-2109, 2012.

S. D. Wiviott, E. Braunwald, C. H. Mccabe, G. Montalescot, W. Ruzyllo et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, vol.357, issue.20, pp.2001-2016, 2007.

L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, vol.361, issue.11, pp.1045-57, 2009.

M. Valgimigli, H. Bueno, R. A. Byrne, J. Collet, F. Costa et al., ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, vol.39, issue.3, pp.213-60, 2017.

N. Verweij, R. N. Eppinga, Y. Hagemeijer, and P. Van-der-harst, Identification of 15 novel risk loci for coronary artery disease and genetic risk of recurrent events, atrial fibrillation and heart failure. Sci Rep, vol.7, p.2761, 201705.

M. Hohl, D. H. Lau, A. Müller, A. D. Elliott, B. Linz et al., Concomitant Obesity and Metabolic Syndrome Add to the Atrial Arrhythmogenic Phenotype in Male Hypertensive Rats, J Am Heart Assoc, vol.6, issue.9, 2017.

B. Gorenek, B. Lundqvist, C. , B. Terradellas, J. Camm et al., Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force, EP Eur, vol.16, issue.11, pp.1655-73, 2014.

G. Lip, J. Collet, M. Haude, R. Byrne, E. H. Chung et al., Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), vol.21, pp.192-195, 2018.

J. M. Siller-matula, B. Jilma, K. Schrör, G. Christ, and K. Huber, Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis, J Thromb Haemost JTH, vol.8, issue.12, pp.2624-2665, 2010.

E. A. Woods, M. L. Ackman, M. M. Graham, S. L. Koshman, R. M. Boswell et al., Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention, Can J Hosp Pharm, vol.69, issue.4, pp.280-285, 2016.

W. Dewilde, T. Oirbans, F. Verheugt, J. C. Kelder, D. Smet et al., Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet Lond Engl, vol.381, issue.9872, pp.1107-1122, 2013.

C. M. Gibson, R. Mehran, C. Bode, J. Halperin, F. Verheugt et al., An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI), Am Heart J, vol.169, issue.4, pp.472-478, 2015.

R. D. Lopes, A. N. Vora, D. Liaw, C. B. Granger, H. Darius et al., An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial, Am Heart J, pp.17-23, 0200.

, APixaban vs, PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF -Full Text ViewClinicalTrials.gov [Internet

P. Vranckx, T. Lewalter, M. Valgimigli, J. G. Tijssen, P. Reimitz et al., Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial, Am Heart J, vol.196, pp.105-117, 2018.

D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen et al., Clinical end points in coronary stent trials: a case for standardized definitions, Circulation, vol.115, issue.17, pp.2344-51, 2007.

R. L. Sacco, S. E. Kasner, J. P. Broderick, L. R. Caplan, J. Connors et al., An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, vol.44, issue.7, pp.2064-89, 2013.

R. Mehran, S. V. Rao, D. L. Bhatt, C. M. Gibson, A. Caixeta et al., Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, vol.123, pp.2736-2783, 2011.

E. Morice and . Le, Existe-t-il des éléments prédictifs de l'implication des médecins généralistes dans les thèses de recherche en médecine générale ?, Exercer, vol.23, issue.100, pp.31-33, 2012.

C. P. Cannon, D. L. Bhatt, J. Oldgren, G. Lip, S. G. Ellis et al., Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation, N Engl J Med, vol.377, issue.16, pp.1513-1537, 2017.

K. A. Fiedler, M. Maeng, J. Mehilli, S. Schulz-schüpke, R. A. Byrne et al., Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial, J Am Coll Cardiol, vol.65, issue.16, pp.1619-1648, 2015.

I. Wustrow, N. Sarafoff, B. Haller, L. Rössner, D. Sibbing et al., Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention, Catheter Cardiovasc Interv, vol.92, issue.7, pp.1239-1285, 2018.

M. Lamberts, J. B. Olesen, M. H. Ruwald, C. M. Hansen, D. Karasoy et al., Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study, Circulation, vol.126, issue.10, pp.1185-93, 2012.

R. D. Lopes, M. Rao, D. N. Simon, L. Thomas, A. J. Fonarow et al., Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease, Am J Med, vol.129, issue.6, pp.592-599, 2016.

S. Eric, A. , B. Neel, M. , K. Uri et al., Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention, J Am Heart Assoc, vol.5, issue.10, p.4310

L. R. Jackson, C. Ju, M. Zettler, J. C. Messenger, D. J. Cohen et al., Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study, JACC Cardiovasc Interv, vol.8, issue.14, pp.1880-1889, 2015.

, Agence nationale de sécurité du médicament et des produits de santé. Traitement par antivitamines K (AVK) : nouvelles informations -Lettre aux professionnels de santé, 2018.

, Enfin une définition internationale consensuelle des saignements

. Medscape, , 2009.

N. Sarafoff, A. Martischnig, J. Wealer, K. Mayer, J. Mehilli et al., Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation, J Am Coll Cardiol, vol.61, issue.20, pp.2060-2066, 2013.

J. M. Ruiz-nodar, F. Marín, J. Sánchez-payá, J. A. Hurtado, J. Valencia-martín et al., Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation, Eur Heart J, vol.30, issue.8, pp.932-941, 2009.

A. Goerst, M. Rondeau-lutz, and J. Weber, Ordonnance de sortie d'hospitalisation: Qu'en attendent les médecins généralistes?, 2018.

, Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI -The AVIATOR 2 Registry -Full Text View -ClinicalTrials.gov

P. Je-m'appelle-elisa and . Remplaçant-en-gironde, Dans le cadre de ma thèse, sous la direction du Dr CAILLEBA Ludivine, assistante chef de clinique dans le service de Professeur COUFFINHAL, je cherche à recueillir des données concernant des patients pris en charge à l'hôpital HautLévêque de 2010 à 2016, traités par une triple thérapie anti-thrombotique, soit l'association d'une double antiagrégation plaquettaire suite à la pose de stent(s) et d'une anticoagulation

, Je m'attache tout particulièrement à réunir les informations suivantes : -l'existence d'antécédent(s) de saignement(s)

, actif(s) lui a/ont été implanté(s) le JJ/MM/AA lors d'un(e) syndrome coronarien aigu ST+/ST-/coronarographie programmée. Le patient qui présentait également un problème de FA/flutter est sorti d'hospitalisation avec un traitement associant

, Pourriez-vous m'aider à recueillir des informations complémentaires qui me sont essentielles dans le cadre de cette étude en remplissant le questionnaire ci-joint

. Vous, , vol.33800

, En cas de question(s), vous pouvez me contacter au 06-**-**-**

, En vous remerciant grandement par avance

, Questionnaire type envoyé QUESTIONNAIRE concernant Mr ou Mme X -Votre patient avait-t-il un/des antécédent(s) d'hémorragies(s) AVANT la mise en route de la triple thérapie par le service de cardiologie ? Oui Non

«. Si and . Oui, préciser la nature de l'épisode et le diagnostic étiologique après investigation : ?????????????????????????????????????????

, A quelle date un des trois traitements de cette triple thérapie semble avoir été interrompu en premier selon vos ordonnances/ observations? (préciser si possible en JJ/MM/AA, sinon approximativement)

, vous ont-elles semblées claires? Oui Non -Votre patient a-t-il consulté un médecin en raison de saignements PENDANT qu'il recevait cette triple thérapie ? Oui Non Si «Oui », préciser la nature de l'/les épisode(s), la date et le lieu de prise en charge (si consultation ou hospitalisation), la notion de surdosage en AVK concomitant ou non : ????????????????????????????????????????????? -Votre patient a-t-il subi un événement thromboembolique malgré la triple thérapie en place ? Oui Non Si « Oui, -Les recommandations données par les cardiologues du CHU concernant la durée de la triple thérapie pour votre patient

, AVC(s) ischémique(s) Infarctus (SCA ST-ou ST+) ou Thrombose(s) de stent

. Embolie, autre(s) : rénale et/ou splénique et/ou des membres inférieurs

». Si-«-oui, hospitalisation et s'il existait un sous dosage en AVK : ????????????????????????????????????????????? -Si un saignement ou un évènement thromboembolique a eu lieu, a-t-il conduit à une modification de la thérapeutique? Oui, mais seulement à une SUSPENSION courte de la triple thérapie

À. Oui and . Un, ARRET définitif d'un ou de deux agent(s) constituant(s) la triple thérapie

. Oui, ex : remplacement d'un antiagrégant par un autre), après une suspension courte ou non

. Non, la triple thérapie a été POURSUIVIE de façon IDENTIQUE, SANS interruption. -Votre patient est-il décédé pendant ce traitement ? Oui Non

». Si-«-oui and . .. ?????????,

. Serment-d'hippocrate,

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonorée et méprisée si j'y manque